CN111440868B - 喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 - Google Patents
喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 Download PDFInfo
- Publication number
- CN111440868B CN111440868B CN202010153995.0A CN202010153995A CN111440868B CN 111440868 B CN111440868 B CN 111440868B CN 202010153995 A CN202010153995 A CN 202010153995A CN 111440868 B CN111440868 B CN 111440868B
- Authority
- CN
- China
- Prior art keywords
- circ
- hsa
- squamous carcinoma
- laryngeal squamous
- molecular marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010041823 squamous cell carcinoma Diseases 0.000 title claims abstract description 62
- 239000003147 molecular marker Substances 0.000 title claims abstract description 25
- 238000001514 detection method Methods 0.000 title abstract description 14
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 38
- 238000003745 diagnosis Methods 0.000 claims abstract description 8
- 230000003211 malignant effect Effects 0.000 claims abstract description 7
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 108091081021 Sense strand Proteins 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 22
- 238000004393 prognosis Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 206010023825 Laryngeal cancer Diseases 0.000 description 9
- 206010023841 laryngeal neoplasm Diseases 0.000 description 9
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 7
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091026815 Competing endogenous RNA (CeRNA) Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010153995.0A CN111440868B (zh) | 2020-03-07 | 2020-03-07 | 喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010153995.0A CN111440868B (zh) | 2020-03-07 | 2020-03-07 | 喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111440868A CN111440868A (zh) | 2020-07-24 |
CN111440868B true CN111440868B (zh) | 2023-09-05 |
Family
ID=71627303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010153995.0A Active CN111440868B (zh) | 2020-03-07 | 2020-03-07 | 喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111440868B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112322729B (zh) * | 2020-09-09 | 2024-01-19 | 深圳市龙岗区耳鼻咽喉医院(深圳市耳鼻咽喉研究所、深圳市龙岗区口腔医学研究所) | 一种喉鳞癌环状rna分子标记物及其检测方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108728540A (zh) * | 2018-06-11 | 2018-11-02 | 北京大学人民医院 | 定量检测pard3基因表达的引物和探针及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008002672A2 (en) * | 2006-06-28 | 2008-01-03 | The Cleveland Clinic Foundation | Targets for use in diagnosis, prognosis and therapy of cancer |
WO2018006171A1 (en) * | 2016-07-05 | 2018-01-11 | University Of Saskatchewan | Methods of identifying and treating cancer patients with an ephb6 deficiency |
-
2020
- 2020-03-07 CN CN202010153995.0A patent/CN111440868B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108728540A (zh) * | 2018-06-11 | 2018-11-02 | 北京大学人民医院 | 定量检测pard3基因表达的引物和探针及其应用 |
Non-Patent Citations (1)
Title |
---|
NIH.hsa_circ_0018169.《Circular RNA Interactome》.2020,Mature Sequence. * |
Also Published As
Publication number | Publication date |
---|---|
CN111440868A (zh) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111778338B (zh) | 一种环状rna生物标志物的应用 | |
CN113201591B (zh) | 一种长链非编码rna及其抑制剂在预防、治疗乳腺癌中的应用 | |
CN107519193B (zh) | 食管鳞癌早期分子诊断标志物及其应用 | |
Tsao et al. | The role of circulating microRNA in hepatocellular carcinoma | |
CN111440868B (zh) | 喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 | |
CN113718035A (zh) | 环状RNA hsa_circ_0003552的应用及检测其的试剂盒 | |
CN111378664B (zh) | 一种环状rna及其应用 | |
Khoshnevisan et al. | A significant upregulation of miR-886-5p in high grade and invasive bladder tumors | |
CN111643516A (zh) | LncRNA XIST及与其结合的miR-132作为抑制胃癌细胞增殖、侵袭与转移的用途 | |
CN107625780B (zh) | 非小细胞肺癌诊断标记物microRNA-1253及在药物和诊断试剂盒中的应用 | |
CN111118007B (zh) | 一种长非编码rna在制备治疗宫颈癌药物中的应用 | |
CN105603117B (zh) | miR-3613用于区分肺鳞癌转移与非转移的miRNA标志物 | |
CN113403306B (zh) | 一种lncRNA分子及其用途 | |
CN111334577A (zh) | 喉鳞癌分子标记物hsa_circ_0004547及检测方法和应用 | |
CN107881237B (zh) | 肺癌诊断标记物microRNA-4317及在药物和诊断试剂盒中的应用 | |
CN111534587A (zh) | 分子标志物5-tRF-His、乳腺癌检测试剂盒及其应用 | |
CN111733247A (zh) | 长链非编码rna在癌症诊治中的应用 | |
CN114958856B (zh) | 长链非编码rna cyp1b1-as1作为乳腺癌生物标志物和治疗靶点的应用 | |
CN110577952A (zh) | 一种长非编码rna在诊断和治疗乳腺癌中的应用 | |
CN111763735B (zh) | 肿瘤差异表达基因及其应用 | |
CN110093419B (zh) | 环状rna的应用、试剂盒和药物组合物及其应用 | |
CN113699234B (zh) | 长链非编码RNA Linc01605在作为胃癌诊断性试剂盒及靶向药物开发中的应用 | |
CN114438207B (zh) | 一种乳腺癌的环状rna生物标志物及其应用 | |
CN112941183B (zh) | 非编码基因miR-187-5p在原发性肝癌诊疗中的应用 | |
CN112646883B (zh) | 一种抗肿瘤的生物标志物及其扩增引物对和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231219 Address after: No. 3004, Longgang Avenue, Longcheng street, Longgang District, Shenzhen, Guangdong 518000 Patentee after: Shenzhen Longgang District Ear Nose and Throat Hospital (Shenzhen Ear Nose and Throat Research Institute Shenzhen Longgang District Stomatology Research Institute) Patentee after: Wu Yongyan Patentee after: Gao Wei Address before: 030001 No. 85 Jiefang South Road, Yingze District, Shanxi, Taiyuan Patentee before: FIRST HOSPITAL OF SHANXI MEDICAL University Patentee before: Wu Yongyan Patentee before: Gao Wei |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240131 Address after: 030001 No. 85 Jiefang South Road, Yingze District, Shanxi, Taiyuan Patentee after: FIRST HOSPITAL OF SHANXI MEDICAL University Country or region after: China Patentee after: Wu Yongyan Patentee after: Gao Wei Address before: No. 3004, Longgang Avenue, Longcheng street, Longgang District, Shenzhen, Guangdong 518000 Patentee before: Shenzhen Longgang District Ear Nose and Throat Hospital (Shenzhen Ear Nose and Throat Research Institute Shenzhen Longgang District Stomatology Research Institute) Country or region before: China Patentee before: Wu Yongyan Patentee before: Gao Wei |
|
TR01 | Transfer of patent right |